R 61837

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 461074

CAS#: 100241-46-1

Description: R 61837 is an antirhinoviral agent.

Chemical Structure

R 61837
CAS# 100241-46-1

Theoretical Analysis

MedKoo Cat#: 461074
Name: R 61837
CAS#: 100241-46-1
Chemical Formula: C16H20N4O
Exact Mass: 284.1637
Molecular Weight: 284.36
Elemental Analysis: C, 67.58; H, 7.09; N, 19.70; O, 5.63

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: R 61837; R-61837; R61837;

IUPAC/Chemical Name: 3-methoxy-6-(4-(m-tolyl)piperazin-1-yl)pyridazine


InChi Code: InChI=1S/C16H20N4O/c1-13-4-3-5-14(12-13)19-8-10-20(11-9-19)15-6-7-16(21-2)18-17-15/h3-7,12H,8-11H2,1-2H3


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

Preparing Stock Solutions

The following data is based on the product molecular weight 284.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Andries K, Dewindt B, Snoeks J, Willebrords R, van Eemeren K, Stokbroekx R, Janssen PA. In vitro activity of pirodavir (R 77975), a substituted phenoxy-pyridazinamine with broad-spectrum antipicornaviral activity. Antimicrob Agents Chemother. 1992 Jan;36(1):100-7. PubMed PMID: 1317142; PubMed Central PMCID: PMC189235.

2: Chapman MS, Minor I, Rossmann MG, Diana GD, Andries K. Human rhinovirus 14 complexed with antiviral compound R 61837. J Mol Biol. 1991 Feb 5;217(3):455-63. PubMed PMID: 1847215.

3: Andries K, Dewindt B, De Brabander M, Stokbroekx R, Janssen PA. In vitro activity of R 61837, a new antirhinovirus compound. Arch Virol. 1988;101(3-4):155-67. PubMed PMID: 2845889.

4: Dewindt B, van Eemeren K, Andries K. Antiviral capsid-binding compounds can inhibit the adsorption of minor receptor rhinoviruses. Antiviral Res. 1994 Sep;25(1):67-72. PubMed PMID: 7811059.

5: Moeremans M, De Raeymaeker M, Daneels G, De Brabander M, Aerts F, Janssen C, Andries K. Study of the parameters of binding of R 61837 to human rhinovirus 9 and immunobiochemical evidence of capsid-stabilizing activity of the compound. Antimicrob Agents Chemother. 1992 Feb;36(2):417-24. PubMed PMID: 1318682; PubMed Central PMCID: PMC188450.

6: Andries K, Dewindt B, Snoeks J, Willebrords R. Lack of quantitative correlation between inhibition of replication of rhinoviruses by an antiviral drug and their stabilization. Arch Virol. 1989;106(1-2):51-61. PubMed PMID: 2548460.

7: Kim KH, Willingmann P, Gong ZX, Kremer MJ, Chapman MS, Minor I, Oliveira MA, Rossmann MG, Andries K, Diana GD, et al. A comparison of the anti-rhinoviral drug binding pocket in HRV14 and HRV1A. J Mol Biol. 1993 Mar 5;230(1):206-27. PubMed PMID: 8383771.

8: Oren DA, Zhang A, Nesvadba H, Rosenwirth B, Arnold E. Synthesis and activity of piperazine-containing antirhinoviral agents and crystal structure of SDZ 880-061 bound to human rhinovirus 14. J Mol Biol. 1996 May 31;259(1):120-34. PubMed PMID: 8648640.

9: Dearden C, al-Nakib W, Andries K, Woestenborghs R, Tyrrell DA. Drug resistant rhinoviruses from the nose of experimentally treated volunteers. Arch Virol. 1989;109(1-2):71-81. PubMed PMID: 2558631.

10: al-Nakib W, Higgins PG, Barrow GI, Tyrrell DA, Andries K, Vanden Bussche G, Taylor N, Janssen PA. Suppression of colds in human volunteers challenged with rhinovirus by a new synthetic drug (R61837). Antimicrob Agents Chemother. 1989 Apr;33(4):522-5. PubMed PMID: 2543283; PubMed Central PMCID: PMC172472.